Jay Pandit, MD
Jay Pandit, MD
  • Is the Faculty Director of the Northwestern University NuVention Biodesign Program, and Assistant Professor in the Northwestern University Feinberg School of Medicine Department of Cardiology.<l/i>
  • Serves as Regional Director of the Bluhm Cardiovascular Institute’s Clinical Trials Unit.
  • Physician Entrepreneur with prior start up experience.
  • Attended Stanford University, Medical School and Internal Medicine training at the University of California San Francisco
  • Cardiovascular Diseases Fellowship Training at Northwestern University.
  • Awarded American Heart Association Innovation Award, has completed a Device Development Fellowship and the LEAD Certificate From the Stanford School of Business.
  • He has executed on multiple clinical trials and is well versed with taking an idea from zero to one and scaling to commercialization.
Taha Keilani, MD
Taha Keilani, MD
  • Currently a Senior Advisor for Pharmaceutical Product Development in Multiple Global Pharmaceuticals / Biotechnology Companies. He has held responsibilities in product development and global regulatory approval. In 2008, he served as Vice President of Clinical Affairs and Chief Medical Officer for Leadiant Biosciences Inc. In 2004, he was Vice President of Medical, Regulatory Affairs and Quality at Avant Immunotherapeutics, Inc. Previouly he worked in global clinical development at Serono Inc. and Fujisawa Healthcare. In these companies, Dr. Keilani’s career has covered multiple therapeutic areas including Nephrology, Transplantation, Immunology, Metabolic Disease, Rheumatology, Gastroenterology, Cardio-Thoracic Surgery, Neurology, Vaccine, Hematology and Oncology. His pharmaceutical career was proceeded by 5-year experience in academic research as an Assistant Professor of Medicine at Northwestern University Medical School in Chicago.
  • Dr Keilani has assumed a leading role in several global regulatory teams that successfully submitted approximately 20 INDs, 4 NDAs, and 2 BLAs. He served as a member of the Executive/Senior Management Team, the Global Rare Disease R&D Committee, and leading Joined Project Scientific Steering Committees with Partners. He also participated in multiple successful due-diligences and integrations of product acquisitions, divestures and mergers.